ARS Pharmaceuticals Inc. (SPRY)
11.86
-0.14 (-1.17%)
At close: Feb 20, 2025, 3:59 PM
11.89
0.30%
After-hours: Feb 20, 2025, 04:59 PM EST
undefined% (undefined)
| Bid | 11.75 |
| Market Cap | 1.15B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.5 |
| PE Ratio (ttm) | -23.71 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.15 |
| Volume | 670,188 |
| Avg. Volume (20D) | 1,245,567 |
| Open | 11.95 |
| Previous Close | 12.00 |
| Day's Range | 11.77 - 12.15 |
| 52-Week Range | 7.50 - 18.51 |
| Beta | undefined |
About SPRY
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California....
Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 23
Stock Exchange NASDAQ
Ticker Symbol SPRY
Website https://ars-pharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for SPRY stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 136.19% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
ARS Pharmaceuticals Inc. is scheduled to release its earnings on Mar 20, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-15.23%
ARS Pharmaceuticals shares are trading lower after...
Unlock content with
Pro Subscription
3 months ago
+2.64%
ARS Pharmaceuticals shares are trading higher after the company announced an exclusive rights licensing with its neffy allergic reaction treatment and ALK-Abello.
